The Inflammatory Bowel Diseases (IBD) Research Group is a multidisciplinary group led from the clinical side by Dr Eugeni Domènech, head of the Gastroenterology & Hepatology Department and the Inflammatory Bowel Diseases Unit at Germans Trias i Pujol University Hospital (HUGTiP) and by Dr Josep Manyé Almero, Principal Investigator for Basic and Translational Research. The group is part of the CIBER Consortium (Spanish Ministry of Science) as well as part of the IBDomics and ENEIDA Consortium for genomic research in immune-mediated inflammatory diseases, of which Dr Domènech is the coordinator.

The Inflammatory Bowel Diseases Unit has conducted cutting-edge research over the last 30 years, integrating clinical and translational reseach. Thus, it has positioned itself as a national and international leader in holistic care for IBD patients, resulting in its recognition and excellence certification by the Ad Qualitatem Foundation. Lately, the unit has initiated innovative research aimed at solving the severe and recurrent complications associated with both ulcerative colitis and Crohn's disease (CD). Understanding, innovating, explaining and training are important and integrated parts of our scientific task with a view to transferring our results to clinical practice. The team combines experts in different skills to ensure that research questions are tackled from the most experimental side (IGTP) to the most clinical side (HUGTP). The research lines are based on innovative research tools, which allow us to generate new hypotheses aimed at the development of a more personalized medicine, better therapies and improved patient management.

Keywords: Ulcerative colitis, Crohn's disease, epitranscriptomic biomarkers, corticorefractoriness, postoperative recurrence, creeping fat as a therapeutic target.

This group can also be referred to as Grup de Recerca en Malalties Inflamatòries Intestinals (GReMII).

Inflammatory Bowel Diseases (IBD) research group

Group Leader

  • Eugeni Domènech, MD, PhD
    Eugeni Domènech, MD, PhD

    Eugeni Domènech, MD, PhD

    Prof Eugeni Domènech started his research activity at the end of his training in gastroenterology as a research fellow at Germans Trias i Pujol University Hospital, from 1994 to 1999. His main field of research in those early years was portal hypertension, but in 1995 he started to focus on Inflammatory Bowel Diseases (IBD). After initial research on the safety of several immunosuppressant-based treatment strategies in IBD, he started his two main research lines on: 1) the pathogenesis, prediction, prevention and management of postoperative recurrence of Crohn's disease; and 2) the epidemiology, prediction and management of steroid refractoriness in ulcerative colitis. In recent years, GReMII (the acronym of the group in Catalan) initiated two new research lines; firstly, IBD in the elderly and the impact of IBD activity on frailty. More recently, the group started clinical and translational research on the role of adipose tissue (mainly visceral fat) in the pathogenesis and clinical outcomes of Crohn's disease.

    Domènech is currently the head of the Gastroenterology & Hepatology Department at Germans Trias i Pujol University Hospital, the president of the Catalan Society of Gastroenterology & Hepatoogy, and professor of Medicine at Universitat Autònoma de Barcelona. He was the president of the Spanish Working Group in Crohn's and Colitis (GETECCU) and is one of the founders and current chair of the Spanish ENEIDA registry of GETECCU.

    Contact: eugenidomenech(ELIMINAR)@gmail.com

  • Josep Manyé, PhD
    Josep Manyé, PhD

    Josep Manyé, PhD

    Contact: jmanye(ELIMINAR)@igtp.cat

Research lines

Ageing and obesity in IBD

Therapeutic efficacy and safety in IBD: Biological agents & JAK inhibitors

Utility of fecal calprotectin in predicting IBD complications

Epitranscriptomic biomarkers for ulcerative colitis corticorefractoriness and postoperative recurrence in Crohn's disease

Development of cutting-edge therapies using acellular strategies targeting adipose tissue for Crohn's disease

Active projects

Search for postsurgical recurrence biomarkers based on Systems Biology in Crohn's disease

PI: Míriam Mañosa
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI18/00892
Start date: 2019
End date: 2023

Pathological involvement of ileal mesenteric fat in Crohn's disease: study of mechanism of  transformation to creeping-fat and its potential as therapeutic target

PI: Josep Manyé
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI20/00420
Start date: 2021
End date: 2023

Assessment of isomiR profiles in inflammatory bowel disease (IBD) and their potential as biomarkers of corticoid response and postsurgical recurrence

PI: Eugeni Domènech
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI22/01498
Start date: 2023
End date: 2025

Scientific publications

Cañete F, Vela E, Calafat M, Clèries M, Mañosa M, Domènech E. Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based studyJournal of Crohn's and Colitis. 2022 Jan 21;16(1):56. DOI: 10.1093/ecco-jcc/jjab232.044

Argüelles-Arias F, Bermejo F, Borrás-Blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therap Adv Gastroenterol. 2022 May 9;15:17562848221086131. DOI: 10.1177/17562848221086131.

Domènech E, Llaó J, Mañosa M, Martín E, Zabana Y, Navarro M, Garcia E, Busquets D, Pineda J, Monfort D, Gutiérrez A, García F, Menchén L, Villoria A. The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study. Journal of Crohn's and Colitis. 2022 Jan 21;16(1):374. DOI: 10.1093/ecco-jcc/jjab232.498.

Zabana Y et al., On Behalf Of The Eneida Registry Of Geteccu. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. J Clin Med. 2022 Jan 14;11(2):421. DOI: 10.3390/jcm11020421.

Ferreiro, R, Silva M, Marín S, Casanova MJ, Mañosa M, González C, Francisco R, Caballol B, Arias L, Piqueras M, Zabana Y, Rivero M, Calvet X, Mesonero F, Trastoy P, Nistal R, Perosanz R, Vega P, Vivo M, Acosta M. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients? Journal of Crohn's and Colitis. 2022 Jan 21;16(1)322-323. DOI: 10.1093/ecco-jcc/jjab232.417.

Vivo M, Urpi M, Senosiain B, Pérez I, Barrio J, Prado L, Oliva B, Roman V, Cano M, Moranta F, Casanova MJ, Ramos L, Iborra M, Marin C, Acosta M, Poyatos R,, Jorquera B, Bujanda L, Zabana Y, Márquez L. Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry). Journal of Crohn's and Colitis. 2022 Jan 21;16(1)208-210. DOI: 10.1093/ecco-jcc/jjab232.246.

García M, Rivero M, Fernandez A, Francisco R, Sicilia B, Mesonero F, Castro L, Casanova MJ, Bertoletti F, Alonso F, García A, Julián B, Calvet X, Acosta M, Jara L, Varela P, Nuñez A, Ricart E, Riestra S, Gisbert J. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD). Journal of Crohn's and Colitis. 2022 Jan 21;16(1)121-123. DOI: 10.1093/ecco-jcc/jjab232.117.

Muñoza C, Calafat M, Gisbert J, Iglesias Eva, Minguez M, Sicilia Beatriz, Esteve M, Gomollón F, Calvet X, Ricart E, Carpio D, Rivero M, Lopez A, Marquez L, Nos P, Cabriada J, Guardiola J, Garcia M, García López S, Garcia E. Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry. Journal of Crohn's and Colitis. 2022 Jan 21;16(1)567. DOI: 10.1093/ecco-jcc/jjab232.775.

Martin A, Horta D, Florez P, Vela M, Mesonero F, Ramos C, García M J, Masnou H, de la Peña-Negro L, Suárez C, Casanova M J, Ortiz M, Peña E, Calvet X, Fernández S J, González C, Piqueras M, Rodríguez I, Sainz E, Bas F, Manceñido N, Ojeda A, Orts B, Sicilia B, Domènech E, Esteve M. Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC projectJournal of Crohn's and Colitis. 2022 Jan:16(1):321-322. DOI: 10.1093/ecco-jcc/jjab232.416

Gutiérrez A et al. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. Front Med (Lausanne). 2022 Feb 1;9:823900. DOI: 10.3389%2Ffmed.2022.823900.

Uchima H, Colán-Hernández J, Aguilar A, Haya J, Domènech E, Moreno V, Marín I. A simple method to determine the proper length of the gastric myotomy during peroral endoscopic myotomy for achalasia. Endoscopy. 2022 Mar;54(3):E85-E87. DOI: 10.1055/a-1388-6444.

Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial. Inflamm Bowel Dis. 2022 Mar 2;28(3):373-384. DOI: 10.1093/ibd/izab073. Erratum in: Inflamm Bowel Dis. 2021 Oct 06.

Suau R, Pardina E, Domènech E, Lorén V, Manyé J. The Complex Relationship Between Microbiota, Immune Response and Creeping Fat in Crohn's Disease. J Crohns Colitis. 2022 Mar 14;16(3):472-489. DOI: 10.1093/ecco-jcc/jjab159.

Fortuny Bauzá M, Cañete Pizarro F, Calm Salvans A, Calafat Sard M, Domènech Morral E. Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab. Gastroenterol Hepatol. 2022 Apr;45 Suppl 1:11-12. DOI: 10.1016/j.gastrohep.2021.05.005.

Hernández-Camba A, Arranz L, Vera I, Carpio D, Calafat M, Lucendo AJ, Taxonera C, Marín S, Garcia MJ, Marín GS, Rodríguez ES, Carbajo AY, De Castro ML, Iborra M, Martin-Cardona A, Rodríguez-Lago I, Busquets D, Bertoletti F, Ausín MS, Tardillo C, Malaves JH, Bujanda L, Castaño A, Domènech E, Ramos L; GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa); Additional member of the Spanish GETECCU group. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. Dig Liver Dis. 2022 May;54(5):635-641. DOI: 10.1016/j.dld.2021.10.002.

Masnou H, Luna D, Castillo E, Galindo M, Ardèvol A, Clos A, Sarrias MR, Armengol C, Bargalló A, Morillas RM, Domènech E. Prevalence and outcomes of acute-on-chronic liver failure among cirrhotic patients admitted for an acute decompensation. Gastroenterol Hepatol. 2022 Jun-Jul;45(6):424-431. DOI: 10.1016/j.gastrohep.2021.05.007.

Rivière P, Bislenghi G, Vermeire S, Domènech E, Peyrin-Biroulet L, Laharie D, D'Hoore A, Ferrante M. Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1201-1204. DOI: 10.1016/j.cgh.2022.02.025.

Riestra S, Taxonera C, Zabana Y, Carpio D, Chaparro M, Barrio J, Rivero M, López-Sanroman A, Esteve M, de Francisco R, Bastida G, García-López S, Mañosa M, Martin-Arranz MD, Pérez-Calle JL, Guardiola J, Muñoz F, Arranz L, Cabriada JL, García-Sepulcre MF, Navarro M, Montoro-Huguet MÁ, Ricart E, Bermejo F, Calvet X, Piqueras M, Garcia-Planella E, Márquez L, Mínguez M, Van Domselar M, Bujanda L, Aldeguer X, Sicilia B, Iglesias E, Alcaín G, Pérez-Martínez I, Rolle V, Castaño-García A, P Gisbert J, Domènech E, On Behalf Of The Eneida Registry From Geteccu. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. J Clin Med. 2022 Jul 5;11(13):3915. DOI: 10.3390/jcm11133915.

Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. J Crohns Colitis. 2022 Jul 14;16(6):946-953. DOI: 10.1093/ecco-jcc/jjab213.

Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):721-735. DOI: 10.1080/17474124.2022.2100759.

Barreiro-de Acosta M et al. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU. J Crohns Colitis. 2022 Aug 4;16(7):1049-1058. DOI: 10.1093/ecco-jcc/jjac016.

Casadó-Llombart S, Velasco-de Andrés M, Català C, Leyton-Pereira A, Gutiérrez-Cózar R, Suárez B, Armiger N, Carreras E, Esteller M, Ricart E, Ordás I, Gisbert JP, Chaparro M, Esteve M, Márquez L, Busquets D, Iglesias E, García-Planella E, Martín-Arranz MD, Lohmann J, Ayata CK, Niess JH, Engel P, Panés J, Salas A, Domènech E, Lozano F; ENEIDA Project of GETECCU. Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease. Front Immunol. 2022 Sep 21;13:966184. DOI: 10.3389/fimmu.2022.966184.

Arístegui J, Alfayate-Miguelez S, Carazo-Gallego B, Garrote E, Díaz-Munilla L, Mendizabal M, Méndez-Hernández M, Doménech E, Ferrer-Lorente B, Unsaín-Mancisidor M, Ramos-Amador JT, Illán-Ramos M, Croche-Santander B, Centeno Malfaz F, Rodríguez-Suárez J, Cotarelo Suárez M, San-Martín M, Ruiz-Contreras J. Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013-2018). Hum Vaccin Immunother. 2022 Nov 30;18(5):2046961. DOI: 10.1080/21645515.2022.2046961.

Iborra M, Moret I, Busó E, García-Giménez JL, Ricart E, Gisbert JP, Cabré E, Esteve M, Márquez-Mosquera L, García-Planella E, Guardiola J, Pallardó FV, Serena C, Algaba-Chueca F, Domenech E, Nos P, Beltrán B. The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn's Disease. Int J Mol Sci. 2022 Dec 14;23(24):15881. DOI: 10.3390/ijms232415881.

Carrasco A, Tristán E, Fernández-Bañares F, Martín-Cardona A, Aceituno M, Zabana Y, Fluvià L, Hernández JM, Lorén V, Manyé J, Salas A, Andújar X, Loras C, Esteve M. Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients. Immun Inflamm Dis. 2022 Oct;10(10):e710. DOI: 10.1002/iid3.710.

Corujo D, Malinverni R, Carrillo-Reixach J, Meers O, Garcia-Jaraquemada A, Le Pannérer MM, Valero V, Pérez A, Del Río-Álvarez Á, Royo L, Pérez-González B, Raurell H, Acemel RD, Santos-Pereira JM, Garrido-Pontnou M, Gómez-Skarmeta JL, Pasquali L, Manyé J, Armengol C, Buschbeck M. MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines. Cell Rep. 2022 Jun 21;39(12):110988. DOI: 10.1016/j.celrep.2022.110988.

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, P Gisbert J, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, J Lucendo A at al., On Behalf Of The Eneida Registry Of Geteccu. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII). J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540.


La malaltia de Crohn i la colitis ulcerosa són el focus d’un nou episodi del pòdcast 'Un bri de ciència'

Avui, Dia Mundial de la Malaltia Inflamatòria Intestinal, l'IGTP estrena el sisè episodi del seu pòdcast 'Un bri de ciència'. L'investigador Josep Manyé explica la recerca del seu grup per combatre aquest conjunt de malalties, i una pacient comparteix les seves vivències amb la malaltia de Crohn.

- Recerca

Identifiquen un gen associat al manteniment de la barrera protectora de l’intestí, factor clau en la malaltia de Crohn

Un equip multidisciplinari d'investigadors de l'IGTP, el servei de Gastroenterologia de l'Hospital  Germans Trias i Pujol i el CIBEREHD han utilitzat la transcriptòmica per combinar dades de bases de dades públiques i de pacients amb malaltia de Crohn i controls. Han identificat que el gen TMIGD1 té un paper important en la pèrdua de la barrera intestinal entre les cèl·lules que recobreixen l'interior de l'intestí prim. El descobriment aporta informació clau sobre els mecanismes biològics de la malaltia de Crohn i obre el camí a teràpies més personalitzades.

+ Notícies


Josep Manyé Almero

(+34) 93 033 05 33